CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 33 enrolled
Drug / intervention
Shingrix vaccinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03771157
NCT03771157Early Ph 1Completed
CompareCT.gov

Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors - A Pilot Study

University of Rochester·interventional·Posted Dec 10, 2018·Updated Mar 15, 2024

In Brief

A Early Phase 1 clinical trial evaluating Shingrix vaccine for Chronic Lymphocytic Leukemia (CLL) and Waldenstrom Macroglobulinemia (WM). Completed, enrolled 33 participants across 1 site.

Detailed Summary

The primary objective of the study is to assess the capability of a patient with Chronic Lymphocytic Leukemia (CLL) or Waldenström Macroglobulinemia (WM) to generate an immune response to the Shingrix vaccine under first-line BTK inhibitors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedDec 10, 2018
Enrollment StartFeb 1, 2019
Primary CompletionSep 1, 2020
Study CompletionAug 3, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.6 years ago

Interventions

Shingrix vaccinedrug

On day one, patients will receive the first of two doses of the Shingrix vaccine administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.